Concerning the letter by Kass and Takimoto (1) in PNAS regarding our recent publication (2), we would like to make the following comments. First, we agree that our results showing a "lack of importance" for cGMP-dependent protein kinase I (cGKI) as a modulator of cardiac hypertrophy only refers to the "basal" condition as we clearly stated in the manuscript (1, 2). We purposely did not use guanylyl cyclase stimulators or phosphodiesterase (PDE) inhibitors in these studies. However, we do note that, particularly under the stress conditions of isoproterenol infusion or aortic constriction, atrial natriuretic peptide is substantially increased. This provides substantial drive on cGMP synthesis. It is possible that cGKI needs to be induced by very high cGMP to have protective effects, although induction is not a requirement for the importance of this kinase in other tissues. The point here is that ablation of cGKI from cardiomyocytes and most other tissues (except vasculature) does not potentiate the ability of transverse aortic constriction (TAC) or isoproterenol (ISO) to cause hypertrophy. To us, this is an observation that needs to be reconciled with current dogma. The degrees of hypertrophy obtained in our studies were equal to or even higher than those obtained in many other studies.
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Another point of the manuscript regards the presumed role of cardiomyocyte PDE5 to mediate sildenafil's ability to ameliorate hypertrophy caused by TAC or ISO. Clearly, in order for sildenafil to have a direct effect on PDE5 in the cardiomyocyte, PDE5 must be expressed there. As noted in the paper, we find no compelling evidence either by PDE activity measurements or Western analyses that PDE5 is expressed, even at low levels, in isolated, purified adult-mouse cardiomyocytes. It is expressed, however, in cardiac myofibroblasts and vascular smooth muscle. Given these data, we feel that it is quite likely that most of the PDE5 measured by many other groups derives from these cell types, particularly where either whole-heart or partially purified cardiomyocyte preparations were used for the PDE5 activity or Western analyses. We do not dispute the observation by several laboratories that PDE5 is expressed in rat neonatal cardiomyocytes (3, 4) . However, because these cells are not yet fully differentiated, they are well-known to be problematic models for many adult heart functions. Of course, all of the compelling genetic data showing antihypertrophic effects of cGMP have been found in adult transgenic mice, not rats (5) .
Therefore, we suggest that some action for sildenafil other than inhibition of cardiomyocyte PDE5 be considered when thinking about the molecular target(s) for this drug. We suggest either that sildenafil acts indirectly through some other cell type (e.g., myofibroblasts or vascular smooth muscle) or that another target in the cardiomyocyte, such as PDE1C, be considered (6) . PDE1C is likely to be at least partially inhibited by the doses of sildenafil administered in most hypertrophy studies, because plasma concentrations of sildenafil fluctuate widely during the day. Fortunately, these possibilities can be tested experimentally, and we and other laboratories are currently in the process of doing so. These results should clarify the best drugs and best targets for cGMP-mediated antihypertrophic therapy. 
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